LoginRegister

    Lupin launches generic version of Pulmicort Respules Inhalation Suspension

    Farhat NasimWritten by Farhat Nasim   |  
    Lupin launches generic version of Pulmicort Respules Inhalation Suspension

    Lupin's product is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL.


    New Delhi: Drug maker Lupin Wednesday said it has launched Budesonide Inhalation Suspension single-dose ampules, used to treat asthma, in the US market.


    The company has launched its generic product after receiving the approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.


    Read Also: Lupin reviews details of US lawsuit on drug price manipulation


    The Mumbai-based company's product is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL.


    It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children from 12 months to 8 years of age.


    As per IMS MAT March 2019 data, the drug had annual sales of around USD 385.4 million in the US, the company said.







    Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.






    Read Also: Lupin receives three USFDA observations for Aurangabad facility
    asthmaasthma treatmentasthma treatment drugAstraZenecaAstraZeneca Pharmaceuticalsbreathing problemBSEBudesonideBudesonide inhalationBudesonide Inhalation Suspensiondrug for asthmaDrug maker Lupingenericinhalationinhalation suspensionLupinlupin sharesNew DelhiPulmicortPulmicort inhalationPulmicort RespulesPulmicort Respules Inhalation SuspensionUSUS Food and Drug AdministrationUSFDA
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X